GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tilray Brands Inc (NAS:TLRY) » Definitions » Intrinsic Value: Projected FCF

Tilray Brands (Tilray Brands) Intrinsic Value: Projected FCF : $0.87 (As of Apr. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Tilray Brands Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-26), Tilray Brands's Intrinsic Value: Projected FCF is $0.87. The stock price of Tilray Brands is $1.78. Therefore, Tilray Brands's Price-to-Intrinsic-Value-Projected-FCF of today is 2.1.

The historical rank and industry rank for Tilray Brands's Intrinsic Value: Projected FCF or its related term are showing as below:

TLRY' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.64   Med: 4.3   Max: 27.67
Current: 2.05

During the past 12 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Tilray Brands was 27.67. The lowest was 1.64. And the median was 4.30.

TLRY's Price-to-Projected-FCF is ranked worse than
60.27% of 599 companies
in the Drug Manufacturers industry
Industry Median: 1.52 vs TLRY: 2.05

Tilray Brands Intrinsic Value: Projected FCF Historical Data

The historical data trend for Tilray Brands's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tilray Brands Intrinsic Value: Projected FCF Chart

Tilray Brands Annual Data
Trend Aug14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.73 0.22 5.80 2.63 0.75

Tilray Brands Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.75 0.82 0.72 0.87

Competitive Comparison of Tilray Brands's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Tilray Brands's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tilray Brands's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tilray Brands's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Tilray Brands's Price-to-Projected-FCF falls into.



Tilray Brands Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Tilray Brands's Free Cash Flow(6 year avg) = $-146.09.

Tilray Brands's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Feb24)*0.8)/Shares Outstanding (Diluted Average)
=(13.878285919786*-146.09072+3358.858*0.8)/754.439
=0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tilray Brands  (NAS:TLRY) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Tilray Brands's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=1.78/0.87428886578323
=2.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tilray Brands Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Tilray Brands's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Tilray Brands (Tilray Brands) Business Description

Address
265 Talbot Street West, Leamington, ON, CAN, N8H 5L4
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products and alcohol.
Executives
Denise M Faltischek officer: Chief Strategy Officer C/O THE HAIN CELESTIAL GROUP, INC., 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042
Mitchell Gendel officer: Global General Counsel EMERALD HOLDING, INC., 100 BROADWAY, 14TH FLOOR, NEW YORK NY 10005
Irwin D Simon director, officer: President & CEO C/O THE HAIN CELESTIAL GROUP INC., 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042
Carl A Merton officer: Chief Financial Officer C/O TILRAY, INC., 745 FIFTH AVENUE, SUITE 1602, NEW YORK NY 10151
Brendan Kennedy director 1920 EASTLAKE AVENUE E., SEATTLE WA 98105
James R. Meiers officer: Head of Canada C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
David G. Hopkinson director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Thomas P. Looney director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Johann Michael Herhalt director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Jodi L. Butts director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
David F Clanachan director TIM HORTONS INC., 874 SINCLAIR ROAD, OAKVILLE A6 L6K 2Y1
Renah Persofsky director 55 PRINCE ARTHUR AVENUE, #604, TORONTO A6 M5R 1B3
Jon Edward Levin officer: Chief Operating Officer 2701 EASTLAKE AVE E, 3RD FLOOR, SEATTLE WA 98102
Michael C. Kruteck officer: Chief Financial Officer 2701 EASTLAKE AVE E, 3RD FLOOR, SEATTLE WA 98102
Rebekah Dopp director 444 LENOX AVENUE, SOUTH ORANGE NJ 07079